Alli gets celebrity spokeswoman in Judd

Share this article:
Alli gets celebrity spokeswoman in Judd
Alli gets celebrity spokeswoman in Judd
GlaxoSmithKline has signed country singer Wynonna Judd to serve as the face of its OTC weight loss drug Alli.

Judd appears in TV and print ads launching this month, and the story of her battle with weight features in a section of the brand's website at myalli.com, where fans can download desktop wallpaper or recipes and enter to win a trip for two to Nashville for a private concert with her.

Advertising was produced by Arnold, while interactive is being handled by IMC2.

In the TV ad, Judd says Alli has given her more “balance” and extra energy with her kids. She addresses the typically modest weight loss benefits of the drug, saying: “It's not so much about the pounds for me – I'm so much more than a number on a scale.” And she hammers home the drug's safety, saying: “Absolutely the most important reason I chose Alli was because it's FDA approved. I can't sit here and tell other people to take something that's not safe.”

Judd is following in her mom's footsteps with her stint talking up the drug. Naomi Judd appeared in a January episode of Sharing Miracles, the half-hour TV show produced by PhRMA, talking about her debilitating bout with Hepatitis C.
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...